nach oben

Erschienen in:

01.08.2015 | Research Paper

Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma

verfasst von: Nicole M. White-Al Habeeb, Ashley Di Meo, Andreas Scorilas, Fabio Rotondo, Olena Masui, Annetta Seivwright, Manal Gabril, Andrew H. A. Girgis, Michael A. Jewett, George M. Yousef

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Clear cell renal cell carcinoma (ccRCC) is an aggressive disease with unpredictable behaviour. Clinical parameters are not always accurate for prognosis prediction. The integration of molecular markers to prognostic models can significantly improve prognostic assessment and consequently patient management. We assessed the expression of alpha-enolase (ENO1) protein by immunohistochemistry in 360 patients with primary ccRCC and correlated its expression with multiple clinicopathological parameters including stage, grade, tumor size, disease-free and overall survival. Cox proportional hazard regression models adjusted for clinicopathological factors were used to test for a link between ENO1 expression and both disease-free and overall survival. We correlated ENO1 mRNA expression with overall survival in an independent set of 428 ccRCC cases from The Cancer Genome Atlas. ENO1 showed cytoplasmic, membranous and nuclear staining patterns. There is a statistically significant negative correlation between ENO1 expression, tumor stage, and grade. ENO1 expression also shows a statistically significant direct correlation with disease-free survival (p = 0.011) and overall survival (p = 0.030) in ccRCC. Patients with higher ENO1 expression had lower hazard ratio of recurrence, although this was not statistically significant (HR = 0.330, p = 0.060). These findings were validated at the mRNA level in an independent set of 428 ccRCC cases which also showed that low ENO1 expression is associated with significantly shorter overall survival. Down-regulation of ENO1 can be a predictor of poor prognosis in ccRCC, and it can be a potential prognostic marker.

Nur mit Berechtigung zugänglich

Chow WH, Dong LM, Devesa SS (2010) Epidemiology and risk factors for kidney cancer. Nat Rev Urol 7(5):245–257PubMedCentralPubMedCrossRef

Lipworth L, Tarone RE, McLaughlin JK (2006) The epidemiology of renal cell carcinoma. J Urol 176(6 Pt 1):2353–2358PubMedCrossRef

Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML (2003) Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27(5):612–624PubMedCrossRef

Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK et al (2013) The international society of urological pathology (ISUP) vancouver classification of renal neoplasia. Am J Surg Pathol 37(10):1469–1489PubMedCrossRef

Feldstein MS, Rhodes DJ, Parker AS, Orford RR, Castle EP (2009) The haphazard approach to the early detection of asymptomatic renal cancer: results from a contemporary executive health programme. BJU Int 104(1):53–56PubMedCrossRef

Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH et al (2013) External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol 14(2):141–148PubMedCentralPubMedCrossRef

Pasic MD, Samaan S, Yousef GM (2013) Genomic medicine: new frontiers and new challenges. Clin Chem 59(1):158–167PubMedCrossRef

Zhai W, Xu YF, Liu M, Zheng JH (2012) Transcriptome network analysis reveals candidate genes for renal cell carcinoma. J Cancer Res Ther 8(1):28–33PubMedCrossRef

Siu KW, DeSouza LV, Scorilas A, Romaschin AD, Honey RJ, Stewart R, Pace K, Youssef Y, Chow TF, Yousef GM (2009) Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry. J Proteome Res 8(8):3797–3807PubMedCrossRef

10.

Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H et al (2013) Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45(8):860–867PubMedCrossRef

11.

White NM, Masui O, Newsted D, Scorilas A, Romaschin AD, Bjarnason GA, Siu KW, Yousef GM (2014) Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. Br J Cancer 110(5):1250–1259PubMedCentralPubMedCrossRef

12.

Metzger GJ, Dankbar SC, Henriksen J, Rizzardi AE, Rosener NK, Schmechel SC (2012) Development of multigene expression signature maps at the protein level from digitized immunohistochemistry slides. PLoS One 7(3):e33520PubMedCentralPubMedCrossRef

13.

Girgis AH, Iakovlev VV, Beheshti B, Bayani J, Squire JA, Bui A, Mankaruos M, Youssef Y, Khalil B, Khella H et al (2012) Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res 72(20):5273–5284PubMedCrossRef

14.

Arai E, Kanai Y (2010) Genetic and epigenetic alterations during renal carcinogenesis. Int J Clin Exp Pathol 4(1):58–73PubMedCentralPubMed

15.

Kroeger N, Klatte T, Chamie K, Rao PN, Birkhauser FD, Sonn GA, Riss J, Kabbinavar FF, Belldegrun AS, Pantuck AJ (2013) Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma. Cancer 119(8):1547–1554PubMedCrossRef

16.

Monzon FA, Alvarez K, Peterson L, Truong L, Amato RJ, Hernandez-McClain J, Tannir N, Parwani AV, Jonasch E (2011) Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod Pathol 24(11):1470–1479PubMedCrossRef

17.

Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA et al (2009) Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 69(11):4674–4681PubMedCentralPubMedCrossRef

18.

Arai E, Ushijima S, Tsuda H, Fujimoto H, Hosoda F, Shibata T, Kondo T, Imoto I, Inazawa J, Hirohashi S et al (2008) Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: its association with DNA methylation alteration and patient outcome. Clin Cancer Res 14(17):5531–5539PubMedCrossRef

19.

Moore LE, Jaeger E, Nickerson ML, Brennan P, De Vries S, Roy R, Toro J, Li H, Karami S, Lenz P et al (2012) Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation. Oncogenesis 1:e14PubMedCentralPubMedCrossRef

20.

Yokomizo A, Yamamoto K, Furuno K, Shiota M, Tatsugami K, Kuroiwa K, Naito S (2010) Histopathologic subtype-specific genomic profiles of renal cell carcinomas identified by high-resolution whole-genome single nucleotide polymorphism array analysis. Oncol Lett 1(6):1073–1078PubMedCentralPubMedCrossRef

21.

Chang YS, Wu W, Walsh G, Hong WK, Mao L (2003) Enolase-alpha is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior. Clin Cancer Res 9(10 Pt 1):3641–3644PubMed

22.

Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, Eisenson D, Narurkar R, Deng P, Nezi L et al (2012) Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488(7411):337–342PubMedCentralPubMedCrossRef

23.

Gao J, Zhao R, Xue Y, Niu Z, Cui K, Yu F, Zhang B, Li S (2013) Role of enolase-1 in response to hypoxia in breast cancer: exploring the mechanisms of action. Oncol Rep 29(4):1322–1332PubMed

24.

Song Y, Luo Q, Long H, Hu Z, Que T, Zhang X, Li Z, Wang G, Yi L, Liu Z et al (2014) Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma. Mol Cancer 13:65PubMedCentralPubMedCrossRef

25.

Hsu KW, Hsieh RH, Lee YH, Chao CH, Wu KJ, Tseng MJ, Yeh TS (2008) The activated Notch1 receptor cooperates with alpha-enolase and MBP-1 in modulating c-myc activity. Mol Cell Biol 28(15):4829–4842PubMedCentralPubMedCrossRef

26.

Feo S, Arcuri D, Piddini E, Passantino R, Giallongo A (2000) ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1). FEBS Lett 473(1):47–52PubMedCrossRef

27.

Lomnytska MI, Becker S, Gemoll T, Lundgren C, Habermann J, Olsson A, Bodin I, Engstrom U, Hellman U, Hellman K et al (2012) Impact of genomic stability on protein expression in endometrioid endometrial cancer. Br J Cancer 106(7):1297–1305PubMedCentralPubMedCrossRef

28.

White NM, Masui O, Desouza LV, Krakovska O, Metias S, Romaschin AD, Honey RJ, Stewart R, Pace K, Lee J et al (2014) Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma. Oncotarget 5(2):506–518PubMedCentralPubMed

29.

White NM, Newsted DW, Masui O, Romaschin AD, Siu KW, Yousef GM (2014) Identification and validation of dysregulated metabolic pathways in metastatic renal cell carcinoma. Tumour Biol 35(3):1833–1846PubMedCrossRef

30.

Khella HW, White NM, Faragalla H, Gabril M, Boazak M, Dorian D, Khalil B, Antonios H, Bao TT, Pasic MD et al (2012) Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses. Tumour Biol 33(1):131–140PubMedCrossRef

31.

Khella HW, Bakhet M, Allo G, Jewett MA, Girgis AH, Latif A, Girgis H, Von Both I, Bjarnason GA, Yousef GM (2013) miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis 34(10):2231–2239PubMedCrossRef

32.

Caramel J, Quignon F, Delattre O (2008) RhoA-dependent regulation of cell migration by the tumor suppressor hSNF5/INI1. Cancer Res 68(15):6154–6161PubMedCrossRef

33.

Shuch B, Amin A, Armstrong AJ, Eble JN, Ficarra V, Lopez-Beltran A, Martignoni G, Rini BI, Kutikov A (2014) Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol 67(1):85–97PubMedCrossRef

34.

Klatte T, Kroeger N, Rampersaud EN, Birkhauser FD, Logan JE, Sonn G, Riss J, Rao PN, Kabbinavar FF, Belldegrun AS et al (2012) Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma. Cancer 118(23):5777–5782PubMedCrossRef

35.

Klatte T, Rao PN, de Martino M, LaRochelle J, Shuch B, Zomorodian N, Said J, Kabbinavar FF, Belldegrun AS, Pantuck AJ (2009) Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 27(5):746–753PubMedCrossRef

36.

La Rochelle J, Klatte T, Dastane A, Rao N, Seligson D, Said J, Shuch B, Zomorodian N, Kabbinavar F, Belldegrun A et al (2010) Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer 116(20):4696–4702PubMedCrossRef

37.

Baloglu H, Cannizzaro LA, Jones J, Koss LG (2001) Atypical endometrial hyperplasia shares genomic abnormalities with endometrioid carcinoma by comparative genomic hybridization. Hum Pathol 32(6):615–622PubMedCrossRef

38.

Yu L, Shi J, Cheng S, Zhu Y, Zhao X, Yang K, Du X, Klocker H, Yang X, Zhang J (2012) Estrogen promotes prostate cancer cell migration via paracrine release of ENO1 from stromal cells. Mol Endocrinol 26(9):1521–1530PubMedCrossRef

39.

Zhou W, Capello M, Fredolini C, Piemonti L, Liotta LA, Novelli F, Petricoin EF (2010) Mass spectrometry analysis of the post-translational modifications of alpha-enolase from pancreatic ductal adenocarcinoma cells. J Proteome Res 9(6):2929–2936PubMedCrossRef

40.

Morgan TM, Seeley EH, Fadare O, Caprioli RM, Clark PE (2013) Imaging the clear cell renal cell carcinoma proteome. J Urol 189(3):1097–1103PubMedCentralPubMedCrossRef

41.

Tang SW, Chang WH, Su YC, Chen YC, Lai YH, Wu PT, Hsu CI, Lin WC, Lai MK, Lin JY (2009) MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells. Cancer Lett 273(1):35–43PubMedCrossRef

42.

Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B et al (2008) HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14(6):435–446PubMedCentralPubMedCrossRef

43.

Metias SM, Lianidou E, Yousef GM (2009) MicroRNAs in clinical oncology: at the crossroads between promises and problems. J Clin Pathol 62(9):771–776PubMedCrossRef

44.

Chen WC, Lin MS, Ye YL, Gao HJ, Song ZY, Shen XY (2012) microRNA expression pattern and its alteration following celecoxib intervention in human colorectal cancer. Exp Ther Med 3(6):1039–1048PubMedCentralPubMed

45.

Beggs AD, Domingo E, McGregor M, Presz M, Johnstone E, Midgley R, Kerr D, Oukrif D, Novelli M, Abulafi M et al (2012) Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN. Oncotarget 3(11):1348–1355PubMedCentralPubMed

46.

Wuttig D, Zastrow S, Fussel S, Toma MI, Meinhardt M, Kalman K, Junker K, Sanjmyatav J, Boll K, Hackermuller J et al (2012) CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases. Int J Cancer 131(5):693–704CrossRef

47.

Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E (2010) Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 58(1):75–83PubMedCrossRef

48.

Gossage L, Eisen T (2010) Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol 7(5):277–288PubMedCrossRef

49.

Lichner Z, Scorilas A, White NM, Girgis AH, Rotstein L, Wiegand KC, Latif A, Chow C, Huntsman D, Yousef GM (2013) The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma. Am J Pathol 182(4):1163–1170PubMedCrossRef

50.

Kroeze SG, Vermaat JS, van Brussel A, van Melick HH, Voest EE, Jonges TG, van Diest PJ, Hinrichs J, Bosch JL, Jans JJ (2010) Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patients. Eur J Cancer 46(18):3375–3382PubMedCrossRef

51.

Faragalla H, Youssef YM, Scorilas A, Khalil B, White NM, Mejia-Guerrero S, Khella H, Jewett MA, Evans A, Lichner Z et al (2012) The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn 14(4):385–392PubMedCrossRef

52.

Iakovlev VV, Gabril M, Dubinski W, Scorilas A, Youssef YM, Faragalla H, Kovacs K, Rotondo F, Metias S, Arsanious A et al (2012) Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study. Lab Invest 92(1):46–56PubMedCrossRef

Titel: Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma
verfasst von: Nicole M. White-Al Habeeb
Ashley Di Meo
Andreas Scorilas
Fabio Rotondo
Olena Masui
Annetta Seivwright
Manal Gabril
Andrew H. A. Girgis
Michael A. Jewett
George M. Yousef
Publikationsdatum: 01.08.2015
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 6/2015
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-015-9725-2

Springer Medizin

Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2015

Molecular targets and pathways involved in liver metastasis of colorectal cancer

Cadherin-11 regulates the metastasis of Ewing sarcoma cells to bone

Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis

Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer

Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR

Dissemination via the lymphatic or angiogenic route impacts the pathology, microenvironment and hypoxia-related drug response of lung metastases

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie